Shuguang Yuan
Co-Founder alphamol
Dr Shuguang Yuan finished his doctoral dissertation with the supports of Maria Curia Fellowship. It was conducted in three different institutes in Europe, including Swiss Federal Institute of Technology Lausanne (EPFL, Switzerland), Polish Academy of Science (Poland) and KULeuven University (Belgium). He has been in the list of “Global Top 2% Scientists” since 2022.
His research is mainly focusing on G protein-coupled receptors (GPCRs) molecular mechanism as well as drug discovery via computational biology and artificial intelligence.
In June 2013, he was awarded with a PhD title with the honor of distinguished thesis. Following that, he was offered the Marie Curie ETH Postdoc Fellowship. In 2014, Dr. Yuan proposed a theory about the activation mechanism and the continuous water channel of GPCRs, which could be used to guide the design of agonist/antagonist molecules.
Furthermore, Dr. Yuan worked in big pharma in Basel in Switzerland for several years. He has advanced several of his designed molecules into clinical trials successfully.
Seminars
- Where has AI demonstrably delivered measurable impact on GPCR hit identification, optimization and candidate selection?
- What benchmarks and validation frameworks do the field need to credibly assess AI platform performance against traditional methods?
- As AI capabilities expand, where does biological expertise and experimental validation remain non negotiable in the decision-making process?
- Establishing confidence in novel GPCR targets through rigorous biological and translational validation
- Overcoming the scientific challenges associated with discovering therapies against receptors with limited historical characterization
- Accelerating progression from target hypothesis to clinical development through an integrated discovery strategy
